The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia
- PMID: 35760920
- DOI: 10.1007/s00280-022-04449-9
The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia
Abstract
Realgar-Indigo naturalis formula (RIF) is a traditional Chinese medicine containing As4S4 and effective in treating acute promyelocytic leukemia (APL). The dose of RIF remains to be determined in pediatric patients. Comparison of plasma arsenic concentrations and toxicity between RIF and arsenic trioxide (ATO) treatment in APL may help to establish an appropriate therapeutic dose of RIF for children. From October 2018 to March 2020, 19 pediatric patients with APL treated with SCCLG-APL protocol were included, 9 in RIF group at 135 mg/kg/day orally three times daily, and 10 in ATO group at 0.16 mg/kg/day intravenously over 12 h daily. Peak and trough plasma arsenic concentrations were assayed at D1, 2, 7 and 14 of induction treatment. Urine arsenic excretions were assessed with spot urine samples and the measurements were adjusted using creatinine. Toxicities were compared between two groups. The plasma arsenic concentration reached steady state at D7 either in the RIF or ATO group, and the mean peak and trough concentrations were similar between two groups (P > 0.05), which were 0.54 μmol/L and 0.48 μmol/L in RIF group, and 0.63 μmol/L and 0.51 μmol/L in ATO group, respectively. Urine arsenic excretion rate was positively correlated with the concentration of plasma arsenic. The rates of treatment-related adverse events were similar in two groups. In conclusion, the dose of RIF at 135 mg/kg/day may be an appropriate therapeutic dose in children with APL. Urine arsenic level can be used as an indicator to estimate plasma arsenic concentration. Trial registration www.clinicaltrials.gov NCT02200978.
Keywords: Acute promyelocytic leukemia; Arsenic concentration; Children; Urine arsenic excration rate.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group.Blood Cancer J. 2023 Dec 5;13(1):178. doi: 10.1038/s41408-023-00949-w. Blood Cancer J. 2023. PMID: 38052803 Free PMC article. Clinical Trial.
-
Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia.Ann Hematol. 2023 Jul;102(7):1713-1721. doi: 10.1007/s00277-023-05270-x. Epub 2023 May 18. Ann Hematol. 2023. PMID: 37199788 Free PMC article.
-
Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.Am J Hematol. 2018 Dec;93(12):1467-1473. doi: 10.1002/ajh.25271. Epub 2018 Oct 20. Am J Hematol. 2018. PMID: 30160789 Free PMC article. Clinical Trial.
-
The simpler, the better: oral arsenic for acute promyelocytic leukemia.Blood. 2019 Aug 15;134(7):597-605. doi: 10.1182/blood.2019000760. Epub 2019 May 21. Blood. 2019. PMID: 31113776 Review.
-
Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia.Front Oncol. 2021 Feb 5;10:597601. doi: 10.3389/fonc.2020.597601. eCollection 2020. Front Oncol. 2021. PMID: 33614484 Free PMC article. Review.
Cited by
-
Long-term outcome of children with acute promyelocytic leukemia: a randomized study of oral versus intravenous arsenic by SCCLG-APL group.Blood Cancer J. 2023 Dec 5;13(1):178. doi: 10.1038/s41408-023-00949-w. Blood Cancer J. 2023. PMID: 38052803 Free PMC article. Clinical Trial.
-
An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications.Cell Death Discov. 2023 Jul 27;9(1):266. doi: 10.1038/s41420-023-01558-z. Cell Death Discov. 2023. PMID: 37500645 Free PMC article. Review.
-
Differentiation syndrome and coagulation disorder - comparison between treatment with oral and intravenous arsenics in pediatric acute promyelocytic leukemia.Ann Hematol. 2023 Jul;102(7):1713-1721. doi: 10.1007/s00277-023-05270-x. Epub 2023 May 18. Ann Hematol. 2023. PMID: 37199788 Free PMC article.
References
-
- Yang MH, Wan WQ, Luo JS et al (2018) Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study. Am J Hematol 93(12):1467–1473. https://doi.org/10.1002/ajh.25271 - DOI - PubMed - PMC
-
- Zhu HH, Wu DP, Jin J et al (2013) Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol 31:4215–4221. https://doi.org/10.1200/JCO.2013.48.8312 - DOI - PubMed
-
- Wang L, Zhou GB, Liu P et al (2008) Dissection of mechanisms of Chinese medicinal formula Realgar-indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci USA 105:4826–4831. https://doi.org/10.1073/pnas.0712365105 - DOI - PubMed - PMC
-
- Bi LL, Ma Q, Wang SQ et al (2005) Treatment of 32 cases with recurring acute promyelocytic leukemia with tablets of composite natural indigo. Zhonghua Er Ke Za Zhi Sep 43(9):702–703. https://doi.org/10.3760/j.issn:0578-1310.2005.09.020 - DOI
-
- Luo XQ, Ke ZY, Huang LB et al (2009) Improved outcome for Chinese children with acute promyelocytic leukemia: a comparison of two protocols. Pediatr Blood Cancer 53(3):325–328. https://doi.org/10.1002/pbc.22042 - DOI - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials